ReviewVaccines2022
Vaccination against Bacterial Infections: Challenges, Progress, and New Approaches with a Focus on Intracellular Bacteria.
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 55 citations in OpenAlex.
- Antimicrobial Strategies in the Era of Resistance: It Is Too Early to Give Up Antibiotic Therapy.International journal of molecular sciences · 2026Review
- Review
- [Use of vaccines to prevent the development of bacterial resistance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Vaccine development againstClinical and experimental vaccine research · 2026Review
- Conserved CD4Nature microbiology · 2026Article
- Temporal Dynamics of T Cell Immunity Induced by TbpBVeterinary sciences · 2026Article
- Use of shotgun immunoproteomics for the development of protein vaccines against Edwardsiella piscicida.Fish & shellfish immunology · 2026Article
- Next-generation mRNA vaccines eliciting robust protection against multidrug-resistant Enterobacteriaceae.NPJ vaccines · 2025Article
- Harnessing gut microbiota to mitigateVirulence · 2025Review
- Leveraging Electron Beam-Inactivated Multi-StrainVaccines · 2025Article
- B-vac a robust software package for bacterial vaccine design.Scientific reports · 2025Article
- Vaccination-induced neutralizing antibodies in immunocompetent hosts correlate with protection against rickettsiae.NPJ vaccines · 2025Article
- Challenges and opportunities in mRNA vaccine development against bacteria.Nature microbiology · 2025Review
- Review
- Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines.Vaccines · 2025Review
- Next-generation vaccines against bacterial pathogens: mRNA and beyond.Frontiers in immunology · 2025Review
- Subtractive proteomics and reverse-vaccinology approaches for novel drug targets and designing a chimeric vaccine againstFrontiers in immunology · 2025Article
- Article
- The United Nations' ambitious roadmap against tuberculosis: opportunities, challenges and the imperative of equity.Future science OA · 2024Article
- mRNA vaccines for infectious diseases - advances, challenges and opportunities.Nature reviews. Drug discovery · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Many bacterial infections are major health problems worldwide, and treatment of many of these infectious diseases is becoming increasingly difficult due to the development of antibiotic resistance, which is a major threat. Prophylactic vaccines against these bacterial pathogens are urgently needed. This is also true for bacterial infections that are still neglected, even though they affect a large part of the world's population, especially under poor hygienic conditions. One example is typhus, a life-threatening disease also known as "war plague" caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.